# Ginkgo Bioworks

> Ginkgo Bioworks is a VC fund in Boston backing Biotechnology and Health Care. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 8
- Last investment: Aug 2025
- Lead investor: 13%
- Last fund: Oct 2019
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/ginkgo-bioworks-inc-
- X (Twitter): https://twitter.com/ginkgo
- Website: http://ginkgobioworks.com
- Facebook: https://www.facebook.com/ginkgo-bioworks-439935809470328

Ginkgo Bioworks is a biotechnology firm. It is a developer of biological engineering products and custom microbes across multiple markets. It designs, engineer, develops, tests, and licenses organisms. It discovers molecules in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. It also provides probiotic bacteria toprotect the body from dangerous infections, and it generates libraries of molecules. It serves cultured ingredients, carbon mitigation, probiotics, and natural product discovery markets.

## Contacts

5 contacts available for Ginkgo Bioworks. Shizune tracks 11 team members at Ginkgo Bioworks. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ginkgo-bioworks?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 50% |
| Health Care | 2 | 25% |
| Renewable Energy | 2 | 25% |
| Organic | 1 | 13% |
| Military | 1 | 13% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Funding Round | 2 | 25% |
| Seed | 1 | 13% |
| Post-IPO Equity | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 63% |
| Israel | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Anna Marie Wagner | SVP, Corporate Development | 2 | https://shizune.co/investors/profile/anna-marie-wagner |
| Barry Canton | Founder | 0 | https://shizune.co/investors/profile/barry-canton |
| Behzad Mahdavi | Senior Vice President Biopharma Manufacturing & Life Sciences Tools | 0 | https://shizune.co/investors/profile/behzad-mahdavi |
| Daniel Robinson | Platform Strategy & Development | 0 | https://shizune.co/investors/profile/daniel-robinson |
| Han Xu | Senior Product Designer | 0 | https://shizune.co/investors/profile/han-xu-0b90 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Phytolon | Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability |  |  | Aug 13, 2025 |  |
| Phytolon | Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability | $14.5M | Series A | Jul 05, 2022 |  |
| Cambium | Cambium develops biomaterials for fields such as defense, space transport, aerospace, and renewable energy. Leveraging the Deep Tech convergence between synthetic biology, materials science, computation & automation, it delivers radical step changes in advanced material performance and sustainability to improve today’s products and enabletomorrow’s. | $8M | Seed | Sep 14, 2021 |  |
| Allonnia | Allonnia is a bioremediation company focused on waste management. |  | Series A | Oct 22, 2020 |  |
| Synlogic | Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalentconditions, including inflammatory bowel disease, cancer, and other metabolic conditions. |  | Post-IPO Equity | Jun 12, 2019 |  |
| Genomatica | Genomatica develops biobased process technologies that enable a better way to produce widely-used chemicals, from alternative feedstocks, with better economics, sustainability, and performance. Genomatica has earned widespread acclaim for its technology; has commercialized processes for the chemical butanediol (for biodegradable plastics andapparel) and for butylene glycol (cosmetics and personal care), and is working on bio-nylon. Awards include the Kirkpatrick Award, for “the most noteworthy chemical engineering technology commercialized in the world” and the ICIS Innovation Award for its Brontide(TM) butylene glycol. |  |  | Oct 03, 2018 |  |
| Joyn Bio | Joyn Bio is a joint venture founded by Bayer and Ginkgo Bioworks developing probiotics for plants to provide growers with next generation solutions to their biggest challenges. Joyn Bio’s first area of focus will be on engineering microbes that provide cereal crops with their nitrogen needs to reduce agriculture’s reliance on nitrogen fertilizerand its environmental impact. Joyn Bio brings together microbiologists, synthetic biologists, plant scientists, and ecologists at its headquarters in Boston, Massachusetts and its plant research facility in West Sacramento, California. | $100M | Series A | Mar 20, 2018 |  |
| Joyn Bio | Joyn Bio is a joint venture founded by Bayer and Ginkgo Bioworks developing probiotics for plants to provide growers with next generation solutions to their biggest challenges. Joyn Bio’s first area of focus will be on engineering microbes that provide cereal crops with their nitrogen needs to reduce agriculture’s reliance on nitrogen fertilizerand its environmental impact. Joyn Bio brings together microbiologists, synthetic biologists, plant scientists, and ecologists at its headquarters in Boston, Massachusetts and its plant research facility in West Sacramento, California. | $100M | Series A | Sep 14, 2017 |  |

8 of 8 investments shown.

## Co-investors
- [Viking Global Investors](https://shizune.co/investors/profile/viking-global-investors) — VC Fund, 3 deals together
- [Arkin Holdings](https://shizune.co/investors/profile/arkin-holdings) — VC Fund, 2 deals together
- [Bayer](https://shizune.co/investors/profile/bayer-ag-germany) — VC Fund, 2 deals together
- [Leaps by Bayer](https://shizune.co/investors/profile/leaps-by-bayer) — VC Fund, 2 deals together
- [Nextgen Nutrition](https://shizune.co/investors/profile/nextgen-nutrition) — VC Fund, 2 deals together
- [Trendlines Group](https://shizune.co/investors/profile/trendlines-group) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Breakthrough Energy Ventures](https://shizune.co/investors/profile/breakthrough-energy-ventures) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [Energy VC Funds in Israel](https://shizune.co/investors/energy-vc-funds-israel)
- [Sustainability VC Funds in Israel](https://shizune.co/investors/sustainability-vc-funds-israel)
- [Impact VC Funds in Israel](https://shizune.co/investors/impact-vc-funds-israel)

## FAQ

### What does Ginkgo Bioworks invest in?

Ginkgo Bioworks invests primarily in Biotechnology, Health Care and Renewable Energy startups, most often at Series A and Funding Round stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Ginkgo Bioworks?

Public channels for Ginkgo Bioworks include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Ginkgo Bioworks?

The team at Ginkgo Bioworks includes Anna Marie Wagner (SVP, Corporate Development), Barry Canton (Founder) and Behzad Mahdavi (Senior Vice President Biopharma Manufacturing & Life Sciences Tools), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co